Segment Reporting (Tables)

9 Months Ended

Sep. 30, 2024

Segment Reporting [Abstract]

Reconciliation of Operating Profit (Loss) from Segments to Consolidated

A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying unaudited consolidated statements of operations is as follows (in millions, except percentages). Prior period amounts have been restated at constant currency to conform to current year presentation.

	Three Months Ended September 30,				Nine Months Ended September 30,
Net Sales	2024		2023		2024		2023
MedSurg	$	1,470	$	1,332	$	4,352	$	3,943
Cardiovascular	2,709		2,167		7,767		6,442
Total net sales of reportable segments	4,179		3,498		12,118		10,385
Impact of foreign currency fluctuations	30		28		68		130
	$	4,209	$	3,527	$	12,186	$	10,515

Income (loss) before income taxes
MedSurg	$	509	$	455	$	1,494	$	1,322
Cardiovascular	842		579		2,256		1,714
Total operating income of reportable segments	1,350		1,034		3,750		3,036
Unallocated amounts:
Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments	(203)		(115)		(472)		(288)
Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs	(209)		(19)		(719)		(370)
Amortization expense	(205)		(208)		(631)		(620)
Operating income (loss)	733		693		1,928		1,759
Other income (expense), net	(65)		(83)		(231)		(279)
Income (loss) before income taxes	$	669	$	610	$	1,697	$	1,480

	Three Months Ended September 30,				Nine Months Ended September 30,
Operating income margin of reportable segments	2024		2023		2024		2023
MedSurg	34.6	%	34.2	%	34.3	%	33.5	%
Cardiovascular	31.1	%	26.7	%	29.0	%	26.6	%